COVID-19 vaccine: AIIMS Delhi to seek permission for phase 3 trial of Bharat Biotech's Covaxin by next week

 Moneycontrol, October 31, 2020


Delhi's All India Institute of Medical Sciences (AIIMS) is likely to submit a proposal to the Institute of Ethics Committee to begin Phase 3 clinical trials of Bharat Biotech's coronavirus vaccine candidate Covaxin by early next week.

Bharat Biotech received approval for Phase 3 trials on October 22. AIIMS Delhi is one of the hospitals selected for the final-stage trials to be conducted across India.

"The proposal is being prepared for the Phase 3 trials and within a couple of days we will be submitting it to the institute of ethics committee for approval," Hindustan Times quoted Dr Sanjay Rai, professor, department of community medicine, AIIMS Delhi, as saying.

AIIMS plans to recruit between 2,000 and 5,000 participants for the trial, the report said.

The Indian Council of Medical Research (ICMR) rules require an ethics committee to oversee clinical research and review the proposal at any site before allowing the trial.

AIIMS ethics committee is likely to take about 10-14 days to grant the approvals.

The third phase of human trials of Covaxin is set to begin at the Indian Institute of Medical Sciences (IMS) and SUM Hospital in Odisha.

The Central Drugs Control Organisation (CDSCO) has given the approval for the third phase trials of Covaxin, said Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and a professor in the Department of Community Medicine at IMS and SUM Hospital.

Bharat Biotech had on October 2 sought the DCGI's permission to conduct phase 3 randomised double-blind placebo-controlled multicentre trial of its vaccine.

In its application, the firm said the study would cover over 28,500 subjects, aged 18 years and above. The study would be conducted at 19 sites in 10 states.

The potential vaccine against COVID-19 is being developed by the Hyderabad-based Bharat Biotech in collaboration with ICMR and the National Institute of Virology. Two doses of the Covaxin are to be administered in a gap of 14 days.

Link:https://www.moneycontrol.com/news/india/covid-19-vaccine-aiims-delhi-to-seek-permission-for-phase-3-trial-of-bharat-biotechs-covaxin-by-next-week-6043641.html

Comments

Post a Comment

Popular posts from this blog

Pakistan's shame: 139 Pakistanis on UN terror list; Hafiz Saeed also named

Business Standard April 05, 2018 Amid its apparent failure to withdraw support and funding to proscribed terrorist organisations, Pakistan is set to be 'grey listed' by the Financial Action Task Force in June. Pakistan continues to be associated with globally-censured terrorists with 139 Pakistani citizens and entities featuring in the United Nations Security Council's (UNSC's) consolidated list of terrorists or terror-supporting organisations. The individuals and entities from the country in the list include Mumbai terrorist attack mastermind Hafeez Saeed's outfit Lashkar-e-Taiba, mafia don Dawood Ibrahim Kaskar and the Haqqanis. The list was released on Tuesday and highlighted names of terrorists who lived in Pakistan, used Pakistani soil for their operations or collaborated with terrorist groups operating from within Pakistan. The list is topped by Osama bin Laden's heir apparent Ayman al-Zawahiri, who was a former operational and military lea...
Read more
 The Telegraph  December 24, 2020 A new, potentially more infectious variant of the novel coronavirus that causes Covid-19 has been found in Britain in cases linked to South Africa, British health secretary Matt Hancock said on Wednesday.  South Africa’s health department said last week that a new genetic mutation of the virus had been discovered and might be responsible for a recent surge in infections there. “Thanks to the impressive genomic capability of the South Africans, we’ve detected two cases of another new variant of coronavirus here in the UK,” Hancock told a media briefing. “Both are contacts of cases who have travelled from South Africa over the past few weeks.”  Britain is already trying to curb the spread of a mutated strain of the virus which is up to 70 per cent more transmissible, and further studies are being carried out on the new variant. “This new variant is highly concerning, because it is yet more transmissible, and it appears to have mutated ...
Read more

CIBIL- SIDBI study: ‘Despite rate cuts & govt push, MSME credit growth slides’

The Indian Express October 17, 2019 Mirroring the deepening slowdown in the economy, commercial lending exposure in the country has declined 2.6 per cent, or Rs 1,70,000 crore, to Rs 63.8 lakh crore in the June quarter of 2019-20 from Rs 65.5 lakh crore in March 2019, said a TransUnion CIBIL- SIDBI study. Despite several rate cuts by the RBI, micro, small and medium enterprises (MSMEs) have recorded a slide in credit exposure. “Entities having less than Rs 25 crore credit exposure have reported a lower credit growth rate of 12 per cent in the year ended June 2019 as against a growth rate of 23.1 per cent last year. Very small segment (less than Rs 10 lakh exposure) have registered a credit growth of only 11.3 per cent in June as against a growth rate of 26.2 per cent last year,” says the study. Of the Rs 63.8-lakh crore commercial lending exposure, micro and SME segments account for Rs 15.7 lakh crore exposure (24.5 per cent of commercial credit outstanding). While mi...
Read more